These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26149529)

  • 1. Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer.
    Folio LR; Turkbey EB; Steinberg SM; Apolo AB
    Eur J Radiol; 2015 Sep; 84(9):1708-14. PubMed ID: 26149529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
    Liu K; Li G; Fan C; Zhou C; Li J
    Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival.
    Abramson RG; Lakomkin N; Hainline A; Kang H; Hutson MS; Arteaga CL
    AJR Am J Roentgenol; 2018 Jan; 210(1):W1-W7. PubMed ID: 29064750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
    Smith AD; Lieber ML; Shah SN
    AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors.
    Alessandrino F; Gujrathi R; Nassar AH; Alzaghal A; Ravi A; McGregor B; Sonpavde G; Shinagare AB
    Eur Urol Oncol; 2020 Oct; 3(5):680-686. PubMed ID: 31412003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volumetric Versus Unidimensional Measures of Metastatic Colorectal Cancer in Assessing Disease Response.
    Lubner MG; Stabo N; Lubner SJ; Del Rio AM; Song C; Pickhardt PJ
    Clin Colorectal Cancer; 2017 Dec; 16(4):324-333.e1. PubMed ID: 28433601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic Contrast-Enhanced Computed Tomography-Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma.
    Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
    Invest Radiol; 2017 Feb; 52(2):103-110. PubMed ID: 27513367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study.
    Lucidarme O; Wagner M; Gillard P; Kim S; Bachet JB; Rousseau B; Mazard T; Louvet C; Chibaudel B; Cohen R; Garcia-Larnicol ML; Gobert A; Henriques J; André T
    Cancer Imaging; 2019 Dec; 19(1):85. PubMed ID: 31818317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.
    Kitajima K; Yamamoto S; Fukushima K; Yamakado K; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Hirota S
    Eur J Radiol; 2016 Mar; 85(3):593-8. PubMed ID: 26860672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
    Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
    AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.
    Smith AD; Gray MR; del Campo SM; Shlapak D; Ganeshan B; Zhang X; Carson WE
    AJR Am J Roentgenol; 2015 Sep; 205(3):W283-93. PubMed ID: 26295664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.
    Krajewski KM; Fougeray R; Bellmunt J; Pons F; Schutz FA; Rosenberg JE; Salhi Y; Choueiri TK
    Eur J Cancer; 2012 Jul; 48(10):1495-502. PubMed ID: 22176867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
    Werner-Wasik M; Xiao Y; Pequignot E; Curran WJ; Hauck W
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):56-61. PubMed ID: 11516851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of CT volumetric measurement with RECIST response in patients with lung cancer.
    Hayes SA; Pietanza MC; O'Driscoll D; Zheng J; Moskowitz CS; Kris MG; Ginsberg MS
    Eur J Radiol; 2016 Mar; 85(3):524-33. PubMed ID: 26860663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative methodology using CT for predicting survival in patients with metastatic colorectal carcinoma: a pilot study.
    Gottlieb RH; Raczyk C; Hanna T; Fora A; Tan W; Nayyar R; Fakih M
    Clin Imaging; 2010; 34(3):196-202. PubMed ID: 20416484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT).
    Beuzit L; Edeline J; Brun V; Ronot M; Guillygomarc'h A; Boudjema K; Gandon Y; Garin E; Rolland Y
    Eur J Radiol; 2016 Aug; 85(8):1445-52. PubMed ID: 27423686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria.
    Schramm N; Englhart E; Schlemmer M; Hittinger M; Übleis C; Becker CR; Reiser MF; Berger F
    Eur J Radiol; 2013 Jun; 82(6):951-8. PubMed ID: 23518148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.